Abbott’s Xience V claims bragging rights as top-selling stent

The economy may be in the dumps but today Abbott reported 10% growth in the last quarter. In addition to strong sales for its blockbuster Humira, company growth was fueled by rapidly growing sales of its Xience V drug-eluting stent. According to Abbott, the Xience V became the US market leader in the fourth quarter.

The Abbott upswing is partly a reflection of a general recovery in confidence with drug-eluting stents, which have now recaptured 70% of the stent market.

Speak Your Mind